Core Insights - The core viewpoint of the articles highlights the resilience and improved profitability of the AI medical company Yidu Tech (医渡科技) as it reports significant growth in revenue and a substantial reduction in losses during the first half of the fiscal year 2026 [1][2] Financial Performance - Total revenue reached RMB 358 million, representing an 8.7% increase compared to the same period last year [1] - Losses decreased by 72% year-on-year, nearing breakeven [1] - Cash flow showed significant improvement, supporting the company's strategic focus and refined operations [2] Business Segments - The AI for Medical segment generated revenue of RMB 153 million, a year-on-year increase of 14.6%, with a customer base expanding to 127 well-known hospitals and 44 regulatory bodies [1] - The AI for Life Science segment reported revenue of RMB 138 million, maintaining high customer retention with 17 out of the top 20 multinational pharmaceutical companies as clients [1] - The AI for Care segment saw a revenue surge of 30.3% to RMB 66.67 million, with the "Shenzhen Huimin Insurance" program reaching over 6.15 million insured individuals [1] Strategic Positioning - The company is positioned well within the AI medical industry as it transitions from technology development to systematic empowerment, supported by ample cash reserves and a comprehensive ecosystem layout [2]
医渡科技(02158)2026财年中期业绩出炉，营收3.58亿元同比增8.7%